Cargando…
Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis
OBJECTIVE: This study sought to determine the effect of the recombinant human growth hormone (rhGH) treatment of Turner syndrome (TS) on height outcome. METHODS: We searched in MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews. A literatur...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900457/ https://www.ncbi.nlm.nih.gov/pubmed/29581156 http://dx.doi.org/10.1530/EC-18-0115 |
_version_ | 1783314416771530752 |
---|---|
author | Li, Ping Cheng, Fei Xiu, Lei |
author_facet | Li, Ping Cheng, Fei Xiu, Lei |
author_sort | Li, Ping |
collection | PubMed |
description | OBJECTIVE: This study sought to determine the effect of the recombinant human growth hormone (rhGH) treatment of Turner syndrome (TS) on height outcome. METHODS: We searched in MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews. A literature search identified 640 records. After screening and full-text assessment, 11 records were included in the systematic review. Methodological quality was assessed using the Cochrane Risk of Bias tool. RevMan 5.3 software was used for meta-analysis. We also assessed the quality of evidence with the GRADE system. RESULTS: Compared with controls, rhGH therapy led to increased final height (MD = 7.22 cm, 95% CI 5.27–9.18, P < 0.001, I2 = 4%; P = 0.18), height standard deviation (HtSDS) (SMD = 1.22, 95% CI 0.88–1.56, P < 0.001, I2 = 49%; P = 0.14) and height velocity (HV) (MD 2.68 cm/year; 95% CI 2.34, 3.02; P < 0.001, I2 = 0%; P = 0.72). There was a small increase in bone age (SMD 0.32 years; 95% CI 0.1, 0.54; P = 0.004, I2 = 73%; P = 0.02) after rhGH therapy for 12 months. What is more, the rhGH/oxandrolone combination therapy suggested greater final height (MD 2.46 cm; 95% CI 0.73, 4.18; P = 0.005, I2 = 32%; P = 0.22), increase and faster HV (SMD 1.67 cm/year; 95% CI 1.03, 2.31; P < 0.03, I2 = 80%; P < 0.001), with no significant increase in HtSDS and bone maturation compared with rhGH therapy alone. CONCLUSIONS: For TS patients, rhGH alone or with concomitant use of oxandrolone treatment had advantages on final height. |
format | Online Article Text |
id | pubmed-5900457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-59004572018-04-19 Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis Li, Ping Cheng, Fei Xiu, Lei Endocr Connect Research OBJECTIVE: This study sought to determine the effect of the recombinant human growth hormone (rhGH) treatment of Turner syndrome (TS) on height outcome. METHODS: We searched in MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews. A literature search identified 640 records. After screening and full-text assessment, 11 records were included in the systematic review. Methodological quality was assessed using the Cochrane Risk of Bias tool. RevMan 5.3 software was used for meta-analysis. We also assessed the quality of evidence with the GRADE system. RESULTS: Compared with controls, rhGH therapy led to increased final height (MD = 7.22 cm, 95% CI 5.27–9.18, P < 0.001, I2 = 4%; P = 0.18), height standard deviation (HtSDS) (SMD = 1.22, 95% CI 0.88–1.56, P < 0.001, I2 = 49%; P = 0.14) and height velocity (HV) (MD 2.68 cm/year; 95% CI 2.34, 3.02; P < 0.001, I2 = 0%; P = 0.72). There was a small increase in bone age (SMD 0.32 years; 95% CI 0.1, 0.54; P = 0.004, I2 = 73%; P = 0.02) after rhGH therapy for 12 months. What is more, the rhGH/oxandrolone combination therapy suggested greater final height (MD 2.46 cm; 95% CI 0.73, 4.18; P = 0.005, I2 = 32%; P = 0.22), increase and faster HV (SMD 1.67 cm/year; 95% CI 1.03, 2.31; P < 0.03, I2 = 80%; P < 0.001), with no significant increase in HtSDS and bone maturation compared with rhGH therapy alone. CONCLUSIONS: For TS patients, rhGH alone or with concomitant use of oxandrolone treatment had advantages on final height. Bioscientifica Ltd 2018-03-26 /pmc/articles/PMC5900457/ /pubmed/29581156 http://dx.doi.org/10.1530/EC-18-0115 Text en © 2018 The authors http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Li, Ping Cheng, Fei Xiu, Lei Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis |
title | Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis |
title_full | Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis |
title_fullStr | Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis |
title_full_unstemmed | Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis |
title_short | Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis |
title_sort | height outcome of the recombinant human growth hormone treatment in turner syndrome: a meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900457/ https://www.ncbi.nlm.nih.gov/pubmed/29581156 http://dx.doi.org/10.1530/EC-18-0115 |
work_keys_str_mv | AT liping heightoutcomeoftherecombinanthumangrowthhormonetreatmentinturnersyndromeametaanalysis AT chengfei heightoutcomeoftherecombinanthumangrowthhormonetreatmentinturnersyndromeametaanalysis AT xiulei heightoutcomeoftherecombinanthumangrowthhormonetreatmentinturnersyndromeametaanalysis |